[3] The company was conceived after Broad Institute researchers Levi Garraway and Matthew Meyerson published a 2007 paper detailing a method for large-panel testing of 238 DNA mutations.

[4] Foundation Medicine launched in 2010 with a $25 million Series A financing led by Third Rock Ventures.

[9] The following year, Priority Health in Michigan became the first healthcare plan in the United States to cover the company's tests.

[14][15] In 2021, Guardant Health licensed intellectual property to Foundation Medicine for $25 million in a settlement.

[16] Foundation Medicine's products include genomic tests for solid tumors and blood-based cancers and sarcomas,[17] as well as data services.